Seelos Therapeutics, Inc.
CIK 0001017491
Revenue (TTM)
$1.7M
Q2 Aug 2024
Net Income (TTM)
$20.04M
+48.5% YoY
Q2 Aug 2024
EPS Diluted (TTM)
−$53.86
+62.7% YoY
Q2 Aug 2024
Gross Margin
160.3%
Q2 Aug 2024
Operating Margin
-1,929.9%
Q2 Aug 2024
Net Margin
1,181.0%
Q2 Aug 2024
Free Cash Flow (TTM)
−$43.81M
Q2 Aug 2024
Cash
$30.51M
Q2 Aug 2024
Total Debt
$10.5M
Q2 Aug 2024
Shares Outstanding
5.96M sh
Q2 Aug 2024
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.